Examining the economic impact of restenosis: Implications for the cost-effectiveness of an antiproliferative stent

Zeitschrift fur Kardiologie

Volumn 91, Issue SUPPL. 3, 2002, Pages 137-143

  Greenberg, Dan ^a   Cohen, David J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Percutaneous transluminal coronary angioplasty; Restenosis; Stent

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN;

ANGIOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; ELUTION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MODEL; MONEY; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIMARY PREVENTION; QUALITY OF LIFE; RESTENOSIS; SURVIVAL TIME; UNITED STATES; ARTICLE; ATHERECTOMY; BRACHYTHERAPY; COMPARATIVE STUDY; COST; ECONOMICS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHERECTOMY; BRACHYTHERAPY; COMPARATIVE STUDY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HUMAN; PRIMARY PREVENTION; QUALITY OF LIFE; STENTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; UNITED STATES; HUMANS;

EID: 0036982386     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-002-1325-x     Document Type: Conference Paper

References (42)

1. Are QALYs an appropriate measure for valuing mortality in acute diseases?
2. Is there a relationship between restenosis and health status following percutaneous coronary revascularization? Results from the BOAT trial
3. In-hospital and follow-up costs of balloon angioplasty and directional atherectomy: Results from the randomized BOAT trial
4. In-hospital and 6-month follow up costs of universal vs. provisional stenting. Results from the DESTINI trial
5. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization, coronary angioplasty, and stenting in 70 catheterization laboratories
6. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model
7. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery
8. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting. Results from the ESPRIT trial
9. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial
10. Economic assessment of gamma-brachytherapy for treatment of in-stent restenosis; results from the Gamma-1 trial
11. Cost-effectiveness of coronary stenting in acute myocardial infarction. Results from the Stent-PAMI trial
12. Use and misuse of the term "cost effective" in medicine
13. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease
14. Cost and health implications of cholesterol lowering
15. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction
16. Cost-effectiveness of HMG-CoA reductase inhibition for primary secondary prevention of coronary heart disease
17. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in porcine model of coronary restenosis
18. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary instent restenosis model
19. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
20. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting
21. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
22. The RAVEL study: A randomized study with sirolimus coated Bx velocity ballon-expandable stent in the treatment of patients with de novo native coronary artery lesions
23. Improved clinical outcome after widespread use of coronary-artery stenting in Canada
24. Costs and clinical outcomes of multivessel coronary stenting compared with bypass surgery: A single-center experience
25. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial
26. FDA approval of coronary-artery brachytherapy
27. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
28. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
29. Cost-effectiveness of adjunctive intracoronary brachytherapy for the treatment of in-stent restenosis
30. Economic outcomes after rotational ablation or balloon angiplasty. Results from the randomized DART trial
31. Sustained supression of neointimal proliferation by sirolimus-eluting stents. One year angiographic and intravascular ultrasound follow-up
32. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
33. Eptifibatide in coronary stent implantation: Long-term results of the ESPRIT trial
34. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
35. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): A randomised trial
36. High-priced technology can be good value for money
37. Foundations of cost effectiveness analysis for health and medical practices
38. Cost-effectiveness of coronary artery bypass surgery
39. Comparison of resource utilization and estimated cumulative cost over 5 years after coronary surgery of coronary angioplasty in patients with two vessel coronary disease abstracted
40. Percutaneous coronary intervention in the current era compared with 1985-1985: The National Heart, Lung, and Blood Institute Registries
41. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of platelet IIb/IIIa inhibitor for stenting trial